机构名称：
¥ 27.0
ABR annualised bleeding rate ADA anti-drug antibodies ADS analysis data set AE adverse event ALT alanine aminotransferase ANCOVA analysis of covariance ANOVA analysis of variance AT antithrombin BMI body mass index BU Bethesda units CACO confirmatory analyses cut-off CI confidence interval CPoC clinical proof of concept CTR clinical trial report DIC disseminated intravascular coagulation DMC data monitoring committee EMA European Medicinal Agency ETD estimated treatment difference ETR estimated treatment ratios FAS full analyses set FDA US Food and Drug Administration FIX coagulation factor IX FVII coagulation factor VII FVIII coagulation factor VIII FXa coagulation factor Xa GCP good clinical practice GFR glomerular filtration rate HA haemophilia A without inhibitors Haem-A-QoL haemophilia quality of life questionnaire for adults HAwI haemophilia A with inhibitors HB haemophilia B without inhibitors HBwI haemophilia B with inhibitors Hemo-TEM haemophilia treatment experience measure H-PPQ the haemophilia patient preference questionnaire ICH international council for harmonisation of technical requirements for pharmaceuticals for human use IPAS intra-patient分析集ISI集成的免疫原性ITEXBR进行处理，而无需重新启动ITEXIR进行审判。对两种方案IU国际单位的患者的初始方案数据的数据，法律上可以接受的代表性LD加载剂量LLOQ LLOQ量化ltfu的下限ltfu丢失了以跟随MI多重插定MMRM混合模型，以重复测量MRD最小稀释
评估报告 - ALHEMO-欧洲药品局
主要关键词
相关文件推荐
